Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Antipsychotic medications are associated with an increased risk of diabetes. We focused on a description of early metabolic adverse effects and clinical and biochemical features that might predict these adverse effects.
Age
18–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-64
Maximum cumulative (lifetime) antipsychotic exposure of one week, and no antipsychotic use in the previous 30 days before enrolling in the study
No history of diabetes or other serious medical or neurological condition associated with glucose intolerance or insulin resistance (eg, Cushing disease),
Not taking a medication associated with insulin resistance (eg, hydrochlorothiazide, furosemide, ethacrynic acid, metolazone, chlorthalidone), beta blockers, glucocorticoids, phenytoin, nicotinic acid, cyclosporine, pentamidine, or narcotics)
No history of cocaine use in the previous 30 days, and
No laboratory evidence of diabetes at baseline (fasting glucose \<126 mg/dL or 2-hour glucose \<200 mg/dL on a glucose tolerance test)
Clareo Health | Diabetes in Neuropsychiatric Disorders
